The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: Preclinical evidence

International Journal of Geriatric Psychiatry

Volumn 18, Issue SUPPL. 1, 2003, Pages

  Danysz, Wojciech ^a   Parsons, Chris G ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Alzheimer's dementia; Cognitive enhancement; Memantine; Neuroprotection; NMDA receptors

Indexed keywords

AMYLOID BETA PROTEIN; DIZOCILPINE; GLUTAMATE RECEPTOR; MAGNESIUM ION; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; COGNITION; CONFERENCE PAPER; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; EVIDENCE BASED MEDICINE; EXPERIMENTAL MODEL; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEARNING; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PASSIVE AVOIDANCE; PATHOGENESIS; SIDE EFFECT; SYMPTOMATOLOGY;

AGED; ALZHEIMER DISEASE; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0141707078     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.938     Document Type: Conference Paper

References (49)

1. Albin RL, Greenamyre JT. 1992. Alternative excitotoxic hypotheses. Neurology 42: 733-738.
2. Bachurin S, Tkachenko S, Baskin I, et al. 2001. Neuroprotective and cognition-enhancing properties of MK-801 flexible analogs. Structure-activity relationships. Ann N Y Acad Sci 939: 219-236.
3. Barnes CA, Danysz W, Parsons CG. 1996. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8: 565-571.
4. Braak H, Braak E, Bohl J. 1993. Staging of Alzheimer-related cortical destruction. Eur Neurol 33: 403-408.
5. 2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J Neurobiol 26: 325-338.
6. Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL. 1992. The time course of glutamate in the synaptic cleft. Science 258: 1498-1501.
7. Cullen WK, Wu JQ, Anwyl R, Rowan MJ. 1996. Beta-amyloid produces a delayed NMDA receptor-dependent reduction in synaptic transmission in rat hippocampus. Neuroreport 8: 87-92.
8. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G. 2000. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - An unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2: 85-97.
9. Ferrarese C, Begni B, Canevari C, et al. 2000. Glutamate uptake is decreased in platelets from Alzheimer's disease patients. Ann Neurol 47: 641-643.
10. Francis PT, Sims NR, Procter AW, Bowen DM. 1993. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease - Investigative and therapeutic perspectives. J Neurochem 60: 1589-1604.
11. 2+ in hippocampal slices. Neuropharmacol 38: 1253-1259.
12. Giulian D, Haverkamp LJ, Li J, et al. 1995. Senile plaques stimulate microglia to release a neurotoxin found in alzheimer brain. Neurochem Int 27: 119-137.
13. Greenamyre JT. 1986. The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 43: 1058-1062.
14. Grilli M, Diodato E, Lozza G, et al. 2000. Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc Natl Acad Sci USA 97: 12822-12827.
15. Guo Q, Fu W, Sopher BL, et al. 1999. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5: 101-106.
16. Harris ME, Carney JM, Cole PS, et al. 1995. Beta-amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: Implications for alzheimer's disease. Neuroreport 6: 1875-1879.
17. +-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem 67: 277-286.
18. Hensley K, Carney JM, Stewart CA, Tabatabaie T, Pye Q, Floyd RA. 1997. Nitrone-based free radical traps as neuroprotective agents in cerebral ischaemia and other pathologies. Int Rev Neurobiol 40: 299-317.
19. Ikonomovic MD, Mizukami K, Warde D, et al. 1999. Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer's disease. Exp Neurol 160: 194-204.
20. Klegeris A, McGeer PL. 1997. Beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J Neurosci Res 49: 229-235.
21. Koh JY, Yang LL, Cotman CW. 1990. β-amyloid protein increases the vulnerability of cultured cortical neurones to excitotoxic damage. Brain Res 533: 315-320.
22. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231-236.
23. Lees GJ. 1993. Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 54: 287-322.
24. Li S, Mallory M, Alford M, Tanaka S, Masliah E. 1997. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 56: 901-911.
25. Lipton SA, Rosenberg PA. 1994. Excitatory amin acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613-622.
26. Lukoyanov NV, Paula-Barbosa MM. 2001. Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. Neurosci Lett 309: 45-48.
27. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. 1996. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol 40: 759-766.
28. Masliah E, Mallory M, Alford M, Tanaka S, Hansesn LA. 1998. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. J Neuropathol Exp Neurol 57: 1041-1052.
29. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. 1992. Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376-389.
30. Mattson MP, Zhu H, Yu J, Kindy MS. 2000. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: Involvement of perturbed calcium homeostasis. J Neurosci 20: 1358-1364.
31. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. 2002. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res 958: 210-221.
32. Misztal M, Frankiewicz T, Parsons CG, Danysz W. 1996. Learning deficits induced by chronic intraventricular infusion of quinolinic acid - Protection by MK-801 and memantine. Eur J Pharmacol 296: 1-8.
33. Moechars D, Dewachter I, Lorent K, et al. 1999. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483-6492.
34. Moechars D, Lorent K, De Strooper B, Dewachter I, Van Leuven F. 1996. Expression in brain of amyloid precursor protein mutated in the alpha- secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J 15: 1265-1274.
35. Noda M, Nakanishi H, Akaike N. 1999. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 92: 1465-1474.
36. Parsons CG, Danysz W, Quack G. 1999. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data. Neuropharmacol 38: 735-767.
37. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. 1993. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacol 32: 1337-1350.
38. Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. 1985. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 82: 4531-4534.
39. Reisberg B, Doody R, Stöffler A, et al. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
40. Rogers J, Morrison JH. 1985. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 5: 2801-2808.
41. Schneider I, Reverse D, Dewachter I, et al. 2001. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem 276: 11539-11544.
42. Stieg PE, Sathi S, Warach S, Le DA, Lipton SA. 1999. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur J Pharmacol 375: 115-120.
43. Wenk GL, Danysz W, Mobley SL. 1994. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 655: 7-11.
44. Wenk GL, Danysz W, Mobley SL. 1995. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmac Env Tox Pharmacol 293: 267-270.
45. Wenk GL, Danysz W, Roice DD. 1996. The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. Neuroreport 7: 1453-1456.
46. Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL. 2000. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 134: 58-65.
47. Winblad B, Poritis N. 1999. Memantine in severe dementia: Results of the M-BEST study (benefit and efficiency in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14: 135-146.
48. Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W. 1997. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacol 36: 961-971.
49. Zajaczkowski W, Quack G, Danysz W. 1996. Infusion of (+)-MK-801 and memantine - Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296: 239-246.